Radiopharmceutical complexes targeting prostate-specific membrane antigen and its combinations

A tissue-targeting chelator of formula (III)

• wherein [Ab] is a monoclonal antibody or an antigen-binding fragment thereof having binding affinity for PSMA.

A combination comprising

• (i) a tissue-targeting compound of formula (I)
• wherein [Ab] is a monoclonal antibody or an antigen-binding fragment thereof having binding affinity for a prostate-specific membrane antigen (PSMA), and
• (ii) a pharmaceutical agent selected from a non-steroidal antiandrogen, a steroidal antiandrogen, an androgen synthesis inhibitor, an antigonadotropin, a PARP inhibitor, an ATR inhibitor, an ATM inhibitor, a DNA-PK inhibitor, an AKT inhibitor, a Pi3K inhibitor, a PSMA-targeting beta emitter, an immune checkpoint inhibitor, an alpha emitter, a vaccine and a chemotherapeutic agent.

(canceled)

(canceled)